Imaging insights into basal ganglia function, Parkinson's disease, and dystonia

The Lancet

Volumn 384, Issue 9942, 2014, Pages 532-544

  Stoessl, A Jon ^a   Lehericy, Stephane ^b,c,d,e,f   Strafella, Antonio P ^g,h  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b INSERM   (France)

^c CNRS   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g UNIVERSITY OF TORONTO   (Canada)

^h TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE;

ABNORMAL PROTEIN DEPOSITION; BASAL GANGLION; BEHAVIOR DISORDER; BRAIN FUNCTION; BRAIN SCINTISCANNING; COGNITIVE DEFECT; DISEASE COURSE; DYSTONIA; HUMAN; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEFECT; REVIEW;

BASAL GANGLIA; BRAIN MAPPING; DISEASE PROGRESSION; DOPAMINE; DYSTONIA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84906318591     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60041-6     Document Type: Review

References (90)

1. M Niethammer, D Eidelberg Metabolic brain networks in translational neurology: concepts and applications Ann Neurol 72 2012 635 647
2. DH Kwon, JM Kim, SH Oh et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease Ann Neurol 71 2012 267 277
3. WR Martin, M Wieler, M Gee Midbrain iron content in early Parkinson disease: a potential biomarker of disease status Neurology 70 2008 1411 1417
4. P Péran, A Cherubini, F Assogna et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature Brain 133 2010 3423 3433
5. RA Menke, J Scholz, KL Miller et al. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study Neuroimage 47 2009 435 441
6. R Nandhagopal, L Kuramoto, M Schulzer et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study Brain 132 2009 2970 2979
7. A Iranzo, F Valldeoriola, F Lomeña et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study Lancet Neurol 10 2011 797 805
8. D García-Lorenzo, C Longo-Dos Santos, C Ewenczyk et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease Brain 136 2013 2120 2129
9. 11C]raclopride displacement and PET Neurology 46 1996 1430 1436
10. R de la Fuente-Fernández, V Sossi, Z Huang et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias Brain 127 2004 2747 2754
11. R de la Fuente-Fernández, JQ Lu, V Sossi et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover Ann Neurol 49 2001 298 303
12. AP Strafella, JH Ko, J Grant, M Fraraccio, O Monchi Corticostriatal functional interactions in Parkinson's disease: a rTMS/[11C]raclopride PET study Eur J Neurosci 22 2005 2946 2952
13. R de la Fuente-Fernández, TJ Ruth, V Sossi, M Schulzer, DB Calne, AJ Stoessl Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease Science 293 2001 1164 1166
14. SC Lidstone, M Schulzer, K Dinelle et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease Arch Gen Psychiatry 67 2010 857 865
15. DJ Scott, CS Stohler, CM Egnatuk, H Wang, RA Koeppe, JK Zubieta Individual differences in reward responding explain placebo-induced expectations and effects Neuron 55 2007 325 336
16. S Lehéricy, M Ducros, PF Van de Moortele et al. Diffusion tensor fiber tracking shows distinct corticostriatal circuits in humans Ann Neurol 55 2004 522 529
17. E Bardinet, M Bhattacharjee, D Dormont et al. A three-dimensional histological atlas of the human basal ganglia. II. Atlas deformation strategy and evaluation in deep brain stimulation for Parkinson disease J Neurosurg 110 2009 208 219
18. RB Postuma, A Dagher Basal ganglia functional connectivity based on a meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications Cereb Cortex 16 2006 1508 1521
19. RC Helmich, LC Derikx, M Bakker, R Scheeringa, BR Bloem, I Toni Spatial remapping of cortico-striatal connectivity in Parkinson's disease Cereb Cortex 20 2010 1175 1186
20. F Esposito, A Tessitore, A Giordano et al. Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa Brain 136 2013 710 725
21. CD Hacker, JS Perlmutter, SR Criswell, BM Ances, AZ Snyder Resting state functional connectivity of the striatum in Parkinson's disease Brain 135 2012 3699 3711
22. RC Helmich, MJ Janssen, WJ Oyen, BR Bloem, I Toni Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor Ann Neurol 69 2011 269 281
23. P Remy, M Doder, A Lees, N Turjanski, D Brooks Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system Brain 128 2005 1314 1322
24. 11C-DASB PET study Neurobiol Dis 40 2010 216 221
25. M Politis, K Wu, C Loane et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants Sci Transl Med 2 2010 38ra46
26. M Carta, T Carlsson, D Kirik, A Björklund Dopamine released from -HT terminals is the cause of L-dopa-induced dyskinesia in parkinsonian rats Brain 130 2007 1819 1833
27. M Politis, K Wu, C Loane et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures Neurology 75 2010 1920 1927
28. I Boileau, JJ Warsh, M Guttman et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with 11C-DASB Mov Disord 23 2008 1776 1780
29. NI Bohnen, DI Kaufer, LS Ivanco et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study Arch Neurol 60 2003 1745 1748
30. ML Müller, NI Bohnen Cholinergic dysfunction in Parkinson's disease Curr Neurol Neurosci Rep 13 2013 377
31. PM Meyer, K Strecker, K Kendziorra et al. Reduced alpha4beta2*- nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease Arch Gen Psychiatry 66 2009 866 877
32. P Piccini, RA Weeks, DJ Brooks Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias Ann Neurol 42 1997 720 726
33. AF Ramlackhansingh, SK Bose, I Ahmed, FE Turkheimer, N Pavese, DJ Brooks Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease Neurology 76 2011 1811 1816
34. LK Van, C Casteels, S Lunskens et al. Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo Neurobiol Aging 33 2012 620
35. Y Ouchi, E Yoshikawa, Y Sekine et al. Microglial activation and dopamine terminal loss in early Parkinson's disease Ann Neurol 57 2005 168 175
36. A Gerhard, N Pavese, G Hotton et al. In vivo imaging of microglial activation with 11C(R)-PK11195 PET in idiopathic Parkinson's disease Neurobiol Dis 21 2006 404 412
37. AL Bartels, AT Willemsen, J Doorduin, EF de Vries, RA Dierckx, KL Leenders 11C-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat Disord 16 2010 57 59
38. A Gerhard, RB Banati, GB Goerres et al. 11C(R)-PK11195 PET imaging of microglial activation in multiple system atrophy Neurology 61 2003 686 689
39. 11C(R)-PK11195 PET in progressive supranuclear palsy Mov Disord 21 2006 89 93
40. 11C(R)-PK11195 PET in corticobasal degeneration Mov Disord 19 2004 1221 1226
41. N Pavese, A Gerhard, YF Tai et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study Neurology 66 2006 1638 1643
42. DR Owen, AJ Yeo, RN Gunn et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 J Cereb Blood Flow Metab 32 2012 1 5
43. DP Bagchi, L Yu, JS Perlmutter et al. Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent PLoS One 8 2013 e55031
44. DT Chien, S Bahri, AK Szardenings et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807 J Alzheimers Dis 34 2013 457 468
45. M Maruyama, H Shimada, T Suhara et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls Neuron 79 2013 1094 1108
46. P Donaghy, AJ Thomas, JT O'Brien Amyloid PET imaging in Lewy body disorders Am J Geriatr Psychiatry 2013 published online July 3. http://dx.doi.org/10.1016/j.jagp.2013.03.001
47. I Litvan, D Aarsland, CH Adler et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI Mov Disord 26 2011 1814 1824
48. N Ibarretxe-Bilbao, C Junque, MJ Marti, E Tolosa Brain structural MRI correlates of cognitive dysfunctions in Parkinson's disease J Neurol Sci 310 2011 70 74
49. D Weintraub, N Dietz, JE Duda et al. Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease Brain 135 2012 170 180
50. N Ibarretxe-Bilbao, C Junque, B Segura et al. Progression of cortical thinning in early Parkinson's disease Mov Disord 27 2012 1746 1753
51. D Weintraub, J Koester, MN Potenza et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients Arch Neurol 67 2010 589 595
52. N Ray, AP Strafella Dopamine, reward, and frontostriatal circuitry in impulse control disorders in Parkinson's disease: insights from functional imaging Clin EEG Neurosci 41 2010 87 93
53. T van Eimeren, B Ballanger, G Pellecchia, JM Miyasaki, AE Lang, AP Strafella Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology 34 2009 2758 2766
54. SS O'Sullivan, K Wu, M Politis et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours Brain 134 2011 969 978
55. R Cools Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease Neurosci Biobehav Rev 30 2006 1 23
56. GJ Wang, ND Volkow, PK Thanos, JS Fowler Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review J Addict Dis 23 2004 39 53
57. JW Buckholtz, MT Treadway, RL Cowan et al. Dopaminergic network differences in human impulsivity Science 329 2010 532
58. TD Steeves, J Miyasaki, M Zurowski et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study Brain 132 2009 1376 1385
59. 11C FLB-457 and PET study Neurobiol Dis 48 2012 519 525
60. T van Eimeren, G Pellecchia, R Cilia et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD Neurology 75 2010 1711 1716
61. VK Neychev, RE Gross, S Lehéricy, EJ Hess, HA Jinnah The functional neuroanatomy of dystonia Neurobiol Dis 42 2011 185 201
62. D Eidelberg, JR Moeller, T Ishikawa et al. The metabolic topography of idiopathic torsion dystonia Brain 118 1995 1473 1484
63. D Eidelberg, JR Moeller, A Antonini et al. Functional brain networks in DYT1 dystonia Ann Neurol 44 1998 303 312
64. M Trost, M Carbon, C Edwards et al. Primary dystonia: is abnormal functional brain architecture linked to genotype? Ann Neurol 52 2002 853 856
65. E Zoons, J Booij, AJ Nederveen, JM Dijk, MA Tijssen Structural, functional and molecular imaging of the brain in primary focal dystonia - a review Neuroimage 56 2011 1011 1020
66. AJ Nelson, DT Blake, R Chen Digit-specific aberrations in the primary somatosensory cortex in Writer's cramp Ann Neurol 66 2009 146 154
67. A Quartarone, M Hallett Emerging concepts in the physiological basis of dystonia Mov Disord 28 2013 958 967
68. RJ Zatorre, RD Fields, H Johansen-Berg Plasticity in gray and white: neuroimaging changes in brain structure during learning Nat Neurosci 15 2012 528 536
69. DC Bragg, IA Armata, FC Nery, XO Breakefield, N Sharma Molecular pathways in dystonia Neurobiol Dis 42 2011 136 147
70. JP Lerch, AP Yiu, A Martinez-Canabal et al. Maze training in mice induces MRI-detectable brain shape changes specific to the type of learning Neuroimage 54 2011 2086 2095
71. JW Mink The basal ganglia and involuntary movements: impaired inhibition of competing motor patterns Arch Neurol 60 2003 1365 1368
72. MR DeLong, T Wichmann Circuits and circuit disorders of the basal ganglia Arch Neurol 64 2007 20 24
73. AH Gittis, AC Kreitzer Striatal microcircuitry and movement disorders Trends Neurosci 35 2012 557 564
74. 18F]spiperone binding in putamen in idiopathic focal dystonia J Neurosci 17 1997 843 850
75. M Carbon, M Niethammer, S Peng et al. Abnormal striatal and thalamic dopamine neurotransmission: genotype-related features of dystonia Neurology 72 2009 2097 2103
76. 11C]-raclopride and positron-emission tomography Neurology 50 1998 1028 1032
77. BJ Snow, TG Nygaard, H Takahashi, DB Calne Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism Ann Neurol 34 1993 733 738
78. M Marjańska, S Lehéricy, R Valabrègue et al. Brain dynamic neurochemical changes in dystonic patients: a magnetic resonance spectroscopy study Mov Disord 28 2013 201 209
79. M Fiorio, D Weise, C Önal-Hartmann, D Zeller, M Tinazzi, J Classen Impairment of the rubber hand illusion in focal hand dystonia Brain 134 2011 1428 1437
80. F Castrop, C Dresel, A Hennenlotter, C Zimmer, B Haslinger Basal ganglia-premotor dysfunction during movement imagination in writer's cramp Mov Disord 27 2012 1432 1439
81. M Niethammer, M Carbon, M Argyelan, D Eidelberg Hereditary dystonia as a neurodevelopmental circuit disorder: evidence from neuroimaging Neurobiol Dis 42 2011 202 209
82. M Argyelan, M Carbon, M Niethammer et al. Cerebellothalamocortical connectivity regulates penetrance in dystonia J Neurosci 29 2009 9740 9747
83. AM Uluǧ, A Vo, M Argyelan et al. Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in mice Proc Natl Acad Sci USA 108 2011 6638 6643
84. VK Neychev, X Fan, VI Mitev, EJ Hess, HA Jinnah The basal ganglia and cerebellum interact in the expression of dystonic movement Brain 131 2008 2499 2509
85. AC Bostan, RP Dum, PL Strick The basal ganglia communicate with the cerebellum Proc Natl Acad Sci USA 107 2010 8452 8456
86. F Brighina, M Romano, G Giglia et al. Effects of cerebellar TMS on motor cortex of patients with focal dystonia: a preliminary report Exp Brain Res 192 2009 651 656
87. M Hamada, G Strigaro, N Murase et al. Cerebellar modulation of human associative plasticity J Physiol 590 2012 2365 2374
88. T Popa, B Velayudhan, C Hubsch et al. Cerebellar processing of sensory inputs primes motor cortex plasticity Cereb Cortex 23 2013 305 314
89. M Tinazzi, M Fiorio, A Fiaschi, JC Rothwell, KP Bhatia Sensory functions in dystonia: insights from behavioral studies Mov Disord 24 2009 1427 1436
90. T Wu, M Hallett The cerebellum in Parkinson's disease Brain 136 2013 696 709